CAM
KPTI icon

Cormorant Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Cormorant Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-20,066
Closed -$3.17M – 88
2015
Q3 		$3.17M Hold
20,066
– – 0.51% 48
2015
Q2 		$8.19M Hold
20,066
– – 1.09% 30
2015
Q1 		$9.21M Sell
20,066
-5,601
-22% -$2.41M 1.42% 20
2014
Q4 		$14.4M Hold
25,667
– – 2.22% 17
2014
Q3 		$13.5M Hold
25,667
– – 2.77% 6
2014
Q2 		$17.9M Buy
25,667
+7,000
+37% +$3.26M 4.75% 4
2014
Q1 		$8.65M Buy
18,667
+12,000
+180% +$6.08M 1.99% 21
2013
Q4 		$2.29M Buy
+6,667
New +$1.84M 0.67% 26

Other funds holding KPTI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cormorant Asset Management's KPTI Position: Q4 2015 in Review

Cormorant Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q4 2015, closing a stake of 20,066 shares — an estimated $3.17M sold.

Cormorant Asset Management first reported a position in KPTI in Q4 2013 and held it in 8 quarters. The position peaked at $17.9M in Q2 2014. 85 funds tracked by Wall St. Rank hold KPTI as of Q4 2015.

  • Cormorant Asset Management reported no remaining Karyopharm Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Cormorant Asset Management sold 20,066 Karyopharm Therapeutics shares in Q4 2015, an estimated $3.17M.
  • Cormorant Asset Management first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 8 quarters.
  • Cormorant Asset Management's Karyopharm Therapeutics position peaked at $17.9M in Q2 2014.
  • 85 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2015.

Based on Cormorant Asset Management's 13F filing for Q4 2015, filed 16 Feb 2016.